biosimilar market

Will biosimilars deliver on expectations?
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Biosimilars Market Taking Off in the United StatesAfter many years of speculation, a number of biosimilar drugs are hitting the U.S. market.
Supreme Court Ruling Raises Biosimilars’ AccessHigh court ruling should make biosimilars available faster.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
Are payers optimistic about biosimilars’ savings?As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Predictions for biosimilars: How market access will play outEarly planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
Inside the U.S., European markets for biosimilarsDespite barriers to their adoption in the U.S. and Europe, biosimilars have produced healthcare savings in Europe. Similar savings are projected for the U.S. market.